Roche【1RO】銘柄情報

Roche Holding AG (1RO) 銘柄情報

リアルタイムのストリーミング引用、アイデア、ライブディスカッションのハブ

プレミアム

通貨

363.80

( - )

買値

360.60

売値

361.60

出来高

0.00

0.00 日の範囲 0.00

270.00 52 週間の範囲 422.00

時価総額

289.446B

前日終値

363.80

始値

時刻

最終取引時間

財務取引量

VWAP

平均取引量 (3 か月)

1,020,677 €

発行済株式数

795,617,637

配当利回り

9.8 (3.11%)

PER

19.31

1 株当たり利益 (EPS)

16.04

歳入

63.36B

純利益

12.88B

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand. The company offers pharma solutions in the therapeutic areas of anaemia, blood and solid tumors, dermatology, haematology, infectious diseases... Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand. The company offers pharma solutions in the therapeutic areas of anaemia, blood and solid tumors, dermatology, haematology, infectious diseases, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It also provides in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and others; diagnostic instruments; and digital health solutions. The company was founded in 1896 and is based in Basel, Switzerland. 詳細を表示

セクター

業界

ウェブサイト

www.roche.com

本社

Basel, Switzerland

設立

1896

Roche Holding AG is listed in the sector of the イタリア証券取引所 with ticker 1RO. The last closing price for Roche was 363.80 €. Over the last year, Roche shares have traded in a share price range of 270.00 € to 422.00 €.

Roche currently has 795,617,637 shares in issue. The market capitalisation of Roche is 289.45 € billion. Roche has a price to earnings ratio (PE ratio) of 19.31.

Roche announces global collaboration with Nurix Therapeutics to co-develop and co-commercialise potential best-in-class BTK degrader bexobrutideg across malignant haematology, immunology and neurology

Roche announces global collaboration with Nurix Therapeutics to co-develop and co-commercialise potential best-in-class BTK degrader bexobrutideg...

FDA accepts New Drug Application for Roche’s giredestrant in ER-positive early-stage breast cancer, the first and only oral SERD with positive phase III results in the curative setting

FDA accepts New Drug Application for Roche’s giredestrant in ER-positive early-stage breast cancer, the first and only oral SERD with positive...

Roche to present new data advancing its obesity portfolio at the American Diabetes Association’s 2026 Scientific Sessions

Roche to present new data advancing its obesity portfolio at the American Diabetes Association’s 2026 Scientific Sessions Late-breaking Phase II...

Roche launches the Liver Disease Panel, the first suite of certified algorithms to support Chronic Liver Disease management

Roche launches the Liver Disease Panel, the first suite of certified algorithms to support Chronic Liver Disease management Roche introduces the...

Roche to present new data at ASCO 2026, reinforcing giredestrant's potential to transform the treatment paradigm in early breast cancer

Roche to present new data at ASCO 2026, reinforcing giredestrant's potential to transform the treatment paradigm in early breast cancer New...

Roche receives CE mark for new blood test to detect Alzheimer's pathology: Elecsys® plasma phosphorylated-tau 217 (pTau217)

Roche receives CE mark for new blood test to detect Alzheimer's pathology: Elecsys® plasma phosphorylated-tau 217 (pTau217) Elecsys® pTau217...

Roche enters into a definitive merger agreement to acquire PathAI to transform AI-driven diagnostics

Roche enters into a definitive merger agreement to acquire PathAI to transform AI-driven diagnostics PathAI’s best-in-class Image Management...

Roche to present extensive data showcasing its industry-leading ophthalmology portfolio at ARVO 2026

Roche to present extensive data showcasing its industry-leading ophthalmology portfolio at ARVO 2026 New real-world data confirm Vabysmo’s potent...

[Ad hoc announcement pursuant to Art. 53 LR] Roche reports strong sales growth of +6% at constant exchange rates in the first quarter of 2026; -5% in CHF due to the significant appreciation of the Swiss franc

[Ad hoc announcement pursuant to Art. 53 LR] Roche reports strong sales growth of +6% at constant exchange rates in the first quarter of 2026; -5...

[Ad-hoc-Mitteilung gemäss Art. 53 KR] Starkes Verkaufswachstum der Roche-Gruppe von +6% zu konstanten Wechselkursen im ersten Quartal 2026; -5% in CHF aufgrund der deutlichen Aufwertung des Schweizer Frankens

[Ad-hoc-Mitteilung gemäss Art. 53 KR] Starkes Verkaufswachstum der Roche-Gruppe von +6% zu konstanten Wechselkursen im ersten Quartal 2026; -5% in...

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	0.4	0.110071546505	363.4	363.4	341.6	40	346.44554455	DE
4	10.8	3.05949008499	353	377	341.6	39	358.95913706	DE
12	-0.2	-0.0549450549451	364	377.8	338	22	357.1245012	DE
26	15.8	4.54022988506	348	422	334	18	366.83032667	DE
52	55.8	18.1168831169	308	422	270	13	351.05940594	DE
156	57.8	18.8888888889	306	422	270	12	350.13237265	DE
260	57.8	18.8888888889	306	422	270	12	350.13237265	DE